Immune Checkpoint Inhibitor–associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies

The objective of our systematic review and meta-analysis was to determine the incidence and outcomes of ICI-associated diarrhea and colitis. Bibliographic databases were searched through August 13, 2019, for observational studies of ICI therapy reporting the incidence and/or treatment of diarrhea or colitis. The primary outcome was ICI-associated diarrhea and colitis. Meta-analyses were performed with random-effects models. Twenty-five studies (N=12,661) were included. All studies had a high risk of bias in at least 1 domain. The overall incidence of diarrhea/colitis was 12.8% [95% confidence interval (CI), 8.8–18.2, I2=96.5]. The incidence was lower in patients treated with anti–programmed cell death 1/programmed death-ligand 1 (4.1%, 95% CI, 2.6–6.5) than in those treated with anti–cytotoxic T-cell lymphocyte–associated antigen 4 (20.1%, 95% CI, 15.9–25.1). The remission of diarrhea and/or colitis was higher in patients treated with corticosteroids plus biologics (88.4%, 95% CI, 79.4–93.8) than in those treated with corticosteroids alone (58.3%, 95% CI, 49.3–66.7, Q=18.7, P
Source: Journal of Immunotherapy - Category: Allergy & Immunology Tags: Clinical Studies Source Type: research